Recently Shandong Weifang Pharmaceutical Factory Co., Ltd. received COS approval for Captopril (API) from EDQM (European Directorate for Quality Medicines). It is the first COS the enterprise received after four years' persistent effort. It indicates the enterprise takes a key step to go into international high-end market.
It is known COS compliance is the inevitable way China's APIs go into the member countries of European Union legally. The enterprise applying for registration must ensure it's product accords with the requirement of GMP. If the enterprise passes COS compliance, the enterprise will get more business opportunities and sale it's product to more countries.